Cargando…

Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety

INTRODUCTION: Poor adherence to antipsychotic medication is common in the treatment of schizophrenia and other psychotic disorders. Paliperidone palmitate 3-monthly (PP3M) is the first long-acting injectable (LAI) antipsychotic to allow for only four medication administrations per year, and although...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnett, Joshua, Pappa, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350408/ https://www.ncbi.nlm.nih.gov/pubmed/37465056 http://dx.doi.org/10.2147/PPA.S410028

Ejemplares similares

Patients’ perspectives on switching from one to three monthly Paliperidone Palmitate a cross-sectional patient satisfaction survey
por: Barnett, J., et al.
Publicado: (2023)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate
por: Elefant, Erica, et al.
Publicado: (2016)

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data)
por: Mauri, Massimo Carlo, et al.
Publicado: (2022)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis
por: Lopez, P. Gil, et al.
Publicado: (2021)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
por: González-Rodríguez, Alexandre, et al.
Publicado: (2015)

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia
por: Basu, Anirban, et al.
Publicado: (2018)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
por: Fernández-Miranda, Juan J., et al.
Publicado: (2021)

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
por: Najarian, Dean, et al.
Publicado: (2021)

Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
por: Giron‐Hernandez, Cesar, et al.
Publicado: (2023)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
por: Voss, Erica A., et al.
Publicado: (2015)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal, Srihari, et al.
Publicado: (2020)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
por: Di Lorenzo, Rosaria, et al.
Publicado: (2022)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study
por: Richarz, Ute, et al.
Publicado: (2023)

Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study
por: Pappa, Sofia, et al.
Publicado: (2020)

Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
por: Li, Gang, et al.
Publicado: (2021)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
por: Takekita, Yoshiteru, et al.
Publicado: (2016)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: A 2-year naturalistic follow-up study
por: Clark, Ivana, et al.
Publicado: (2021)

Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety
por: Fernández-Miranda, Juan J, et al.
Publicado: (2023)

Relapse and frequency of injection of monthly paliperidone palmitate—A retrospective case–control study
por: Laing, Emily, et al.
Publicado: (2021)

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
por: Gomeni, Roberto, et al.
Publicado: (2022)

Impact of early use of long acting paliperidone (1 and 3 monthly) in a first-episode psychosis sample
por: Lopez, P. Gil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npdv1ikmqma72q03841emq00mb